Our Partners

Sister Organizations

Established in 1991, the Hepatitis B Foundation is the world’s only nonprofit organization solely dedicated to public health education, research, outreach, awareness, and advocacy in the hepatitis B space.

The PABC is managed by the Blumberg Institute and led by a board appointed by Hepatitis B Foundation – is a nonprofit life sciences incubator-accelerator of more than 50 biotechnology, pharmaceutical, and research companies created to maximize cross-industry synergies and launch new ideas that make a difference.

Shared Mission

Vision

The Hepatitis B Foundation, Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center are nonprofit organizations working in a shared ecosystem to foster scientific innovation to create a world free of hepatitis B and liver cancer.

Mission

The Pennsylvania Biotechnology Center is the home for the Hepatitis B Foundation and The Baruch S. Blumberg Institute, fostering a collaborative environment for early-stage life science companies to thrive and contribute to the mission of curing Hepatitis B and Liver Cancer. The Hepatitis B Foundation is the global leader in public health, policy and advocacy to eliminate hepatitis B and liver cancer. The Baruch S. Blumberg Institute is a research organization dedicated to finding a cure for hepatitis B and liver cancer.

Values

The three organizations are dedicated to upholding evidence-based scientific discovery in a collaborative environment that prioritizes integrity, teamwork, equity, respect, and inclusion of all community members.

Partner Organizations

The Baruch S. Blumberg Institute fosters impactful global collaborations to pioneer the development of early detection biomarkers and therapeutics for liver diseases and cancers. Through our partnerships, we aim to cultivate a diverse cohort of aspiring researchers while nurturing entrepreneurship and innovation in biotechnology. By maximizing resources and fostering collective effort, the institute is dedicated to advancing scientific breakthroughs and ultimately finding cures for these diseases.

University of Pennsylvania

Students enrolled in the Master of Chemical Sciences program can complete research at the Blumberg Institute on either a full- or part-time basis, enabling students to pursue education without interrupting their careers.

Wistar Institute, Philadelphia

Blumberg Institute scientists and Pennsylvania Biotechnology Center (PABC) member companies collaborate with and benefit from Wistar’s growing pipeline of innovative biotechnologies, oncological and immunological therapies, and vaccine and diagnostic assets.

Xavier University School of Medicine, Aruba

A joint master’s in biotechnology degree will be earned at both Xavier University (first year) and the Blumberg Institute (second year) to integrate classroom academics with hands-on research experience. The Blumberg Institute will also host medical research fellows from Xavier University for 12-week rotations.

Central Bucks School District

PABC and Blumberg Institute scientists, funded by Hepatitis B Foundation, have hosted a daily AP Chemistry Class for select students from each of the Central Bucks School District’s three high schools since 2018. Students gain hands-on laboratory experience, assigned mentorship, independent research skills, and relevant after-school enrichment through internships at PABC-member companies and Blumberg labs.

Capital Health Cancer Center, Pennington, N.J.

Since gaining access to their new biorepository (tissue bank) in 2020, The Blumberg Institute scientists have collaborated on clinical research with Capital Health physicians to develop earlier detection methods, new cancer therapies, and personalized medicine.

Patient Communities

The Hepatitis B Foundation continually works to help people living with hepatitis B share their perspectives.

We expanded our #justB and #BtheVoice storytelling programs, adding more than 30 new storytellers from Taiwan, the Philippines and the U.S. in 2023. Their videos, posted on our Hepatitis B stories website, are elevating the voices of people living with hepatitis B. They describe struggles with anxiety, stigma, discrimination and accessing appropriate medical care. They also describe the beauty of lives full of love and support from family and friends.

The Hepatitis B Foundation also strives to include people living with hepatitis B in the drug development process. A major step forward took place in 2020 with an unprecedented meeting authorized by the U.S. Food and Drug Administration (FDA), the first-ever Externally Led Patient-Focused Drug Development dedicated to hepatitis B [details here].

The Hepatitis B Foundation also manages three Community Advisory Boards (CABs), which have a worldwide reach and are composed primarily of people living with hepatitis B.